Terms: = Leukemia AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Clinical Outcome
43 results:
1. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N
Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853
[TBL] [Abstract] [Full Text] [Related]
2. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser S; Martínez-Cuadrón D; Hanoun M; Stölzel F; Gil C; Reinhardt HC; Aguiar E; Schäfer-Eckart K; Burgues JMB; Steffen B; Bernal T; Krause SW; Riaza R; Schliemann C; Cervera J; Kaufmann M; Torres-Miñana L; Hänel M; Acuña-Cruz E; Jost E; Algarra JL; Crysandt M; Fransecky L; Cornago-Navascues J; Kraus S; Martinez-Lopez J; Einsele H; Niemann D; Neubauer A; Seggewiß-Bernhardt R; Scholl S; Klein SA; Schmid C; Schaich M; Schmidt-Hieber M; Zukunft S; Ho AD; Platzbecker U; Baldus CD; Müller-Tidow C; Thiede C; Bornhäuser M; Serve H; Levis M; Montesinos P; Röllig C; Schlenk RF
Haematologica; 2023 Jan; 108(1):34-41. PubMed ID: 35678031
[TBL] [Abstract] [Full Text] [Related]
3. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia.
Xu Q; Guo T
Hematology; 2022 Dec; 27(1):659-671. PubMed ID: 35666642
[No Abstract] [Full Text] [Related]
4. Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia.
Cao Y; Liu Y; Shang L; Chen H; Yue Y; Dong W; Guo Y; Yang H; Yang X; Liu Y; Gu W; Zhang X
Int J Clin Oncol; 2022 Jul; 27(7):1222-1232. PubMed ID: 35536524
[TBL] [Abstract] [Full Text] [Related]
5. The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage.
Huang J; Zhou J; Xiao M; Mao X; Zhu L; Liu S; Li Q; Wang J; Zhou J; Cai H; Wang G
Sci Rep; 2021 Dec; 11(1):24290. PubMed ID: 34934076
[TBL] [Abstract] [Full Text] [Related]
6. The factors influencing clinical outcomes after leukapheresis in acute leukaemia.
Lee H; Park S; Yoon JH; Cho BS; Kim HJ; Lee S; Kim DW; Chung NG; Cho B; Kim KB; Yoo J; Jekarl DW; Chae H; Lim J; Kim M; Oh EJ; Kim Y
Sci Rep; 2021 Mar; 11(1):6426. PubMed ID: 33742034
[TBL] [Abstract] [Full Text] [Related]
7. CCAAT enhancer binding protein alpha (cebpa) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
Wilhelmson AS; Porse BT
Br J Haematol; 2020 Aug; 190(4):495-507. PubMed ID: 32086816
[TBL] [Abstract] [Full Text] [Related]
8. Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia.
Wang J; Ye W; Yan X; Guo Q; Ma Q; Lin F; Huang J; Jin J
J Transl Med; 2019 May; 17(1):149. PubMed ID: 31077215
[TBL] [Abstract] [Full Text] [Related]
9. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract] [Full Text] [Related]
10. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract] [Full Text] [Related]
11.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract] [Full Text] [Related]
12. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
13. clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.
Gao N; Yu WZ; Guo NJ; Wang XX; Sun JR
Leuk Lymphoma; 2017 Jun; 58(6):1394-1402. PubMed ID: 27736291
[TBL] [Abstract] [Full Text] [Related]
14. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract] [Full Text] [Related]
15. Normal karyotype acute myeloid leukemia patients with cebpa double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract] [Full Text] [Related]
16. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
[TBL] [Abstract] [Full Text] [Related]
17. Favorable prognosis of biallelic cebpa gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract] [Full Text] [Related]
18. clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A; Abdelali RB; Chevret S; Nibourel O; Cheok M; Pautas C; Duléry R; Boyer T; Cayuela JM; Hayette S; Raffoux E; Farhat H; Boissel N; Terre C; Dombret H; Castaigne S; Preudhomme C
Oncotarget; 2014 Feb; 5(4):916-32. PubMed ID: 24659740
[TBL] [Abstract] [Full Text] [Related]
19. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract] [Full Text] [Related]
20. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Tejero R; Díaz T; Pratcorona M; Tormo M; Ribera JM; Escoda L; Duarte R; Gallardo D; Heras I; Queipo de Llano MP; Bargay J; Monzo M; Sierra J; Navarro A; Esteve J;
Leukemia; 2014 Apr; 28(4):804-12. PubMed ID: 24072101
[TBL] [Abstract] [Full Text] [Related]
[Next]
